Literature DB >> 8514460

Mutation and expression of the p53 gene in malignant melanoma cell lines.

J Weiss1, K Schwechheimer, W K Cavenee, M Herlyn, K C Arden.   

Abstract

Three monoclonal antibodies (MAbs) against p53 protein (PAb 24o, DO-I and PAb1801) were used to define the immunophenotype of 13 melanoma cell lines. Immunoreactions could be detected in 12 out of 13 cell lines by using the indirect immunofluorescence technique. In 7 of these the majority of cells displayed cytoplasmic staining whereas positive nuclei were detected in only a few cells. Two cell lines had predominantly nuclear reactivity, while the remaining 3 cell lines showed signals in both locations. Despite identical nuclear staining patterns, the 3 MAbs produced qualitatively distinct cytoplasmic immunoreactions. PAb240 and DO-1, which showed similar staining frequencies, appeared more sensitive in the detection of p53 protein than did PAb1801. Immunoprecipitations of lysates from each of the cell lines, with MAbs DO-1 and 1801 (which bind to both wild-type and mutant p53 species) detected 53-kDa proteins, whereas PAb240 (which recognizes the mutant conformation of the protein in this type of assay) detected 53-kDa proteins in only 4 cell lines. Nucleotide sequencing of exons 5 to 9 of TP53 in these latter cell lines showed that each has homozygous point mutations in the locus, whereas in the others no TP53 alterations were found. Three of the 4 mutations were C-to-T transversions, alterations possibly caused by damage from UV-light. Our findings indicate that immunostaining with p53 antibodies, although common in malignant melanoma, results from the presence of mutant p53 protein in about 30% of the cases tested. Neither immunostaining with PAb240 nor the patterns of intracellular distributions of the signals are sufficient to detect TP53 mutations.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8514460     DOI: 10.1002/ijc.2910540427

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  20 in total

1.  Rapid parallel mutation scanning of gene fragments using a microelectronic protein-DNA chip format.

Authors:  Heike A Behrensdorf; Marc Pignot; Norbert Windhab; Andreas Kappel
Journal:  Nucleic Acids Res       Date:  2002-07-15       Impact factor: 16.971

2.  Cell growth and p53 expression in primary acquired melanosis and conjunctival melanoma.

Authors:  S Seregard
Journal:  J Clin Pathol       Date:  1996-04       Impact factor: 3.411

3.  Expression patterns of the p53 tumor suppressor gene and the mdm2 proto-oncogene in human meningiomas.

Authors:  M J Pykett; J Landers; D L George
Journal:  J Neurooncol       Date:  1997-03       Impact factor: 4.130

4.  Point mutations and allelic loss in the TP53 locus of cutaneous malignant melanomas.

Authors:  J Weiss; W K Cavenee; R A Herbst; E G Jung; K C Arden
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

5.  Ubiquitin proteasomal pathway mediated degradation of p53 in melanoma.

Authors:  Adil Anwar; David A Norris; Mayumi Fujita
Journal:  Arch Biochem Biophys       Date:  2010-12-15       Impact factor: 4.013

Review 6.  Metabolic strategies of melanoma cells: Mechanisms, interactions with the tumor microenvironment, and therapeutic implications.

Authors:  Grant M Fischer; Y N Vashisht Gopal; Jennifer L McQuade; Weiyi Peng; Ralph J DeBerardinis; Michael A Davies
Journal:  Pigment Cell Melanoma Res       Date:  2017-11-02       Impact factor: 4.693

7.  The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes.

Authors:  Hong Yu; Ronan McDaid; John Lee; Patricia Possik; Ling Li; Suresh M Kumar; David E Elder; Patricia Van Belle; Phyllis Gimotty; Matt Guerra; Rachel Hammond; Katharine L Nathanson; Maria Dalla Palma; Meenhard Herlyn; Xiaowei Xu
Journal:  Am J Pathol       Date:  2009-04-23       Impact factor: 4.307

8.  Bcl-2 expression in human melanocytes and melanocytic tumors.

Authors:  J J van den Oord; N Vandeghinste; M De Ley; C De Wolf-Peeters
Journal:  Am J Pathol       Date:  1994-08       Impact factor: 4.307

9.  Lack of p53 mutations and loss of heterozygosity in non-cultured human melanocytic lesions.

Authors:  T Papp; M Jafari; D Schiffmann
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

10.  Expression of the p53 protein in malignant melanomas as a prognostic indicator.

Authors:  M Yamamoto; H Takahashi; K Saitoh; T Horikoshi; M Takahashi
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.